List of Excipients in Branded Drug ISOPROTERENOL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	ISOPROTERENOL HYDROCHLORIDE	isoproterenol hydrochloride	68682-433	ANHYDROUS CITRIC ACID
Oceanside Pharmaceuticals	ISOPROTERENOL HYDROCHLORIDE	isoproterenol hydrochloride	68682-433	EDETATE DISODIUM
Oceanside Pharmaceuticals	ISOPROTERENOL HYDROCHLORIDE	isoproterenol hydrochloride	68682-433	HYDROCHLORIC ACID

Generic Drugs Containing ISOPROTERENOL

Company	Ingredient	NDC	Excipient
Cipla USA Inc	isoproterenol hydrochloride	69097-521	CITRIC ACID ACETATE
Cipla USA Inc	isoproterenol hydrochloride	69097-521	EDETATE DISODIUM
Cipla USA Inc	isoproterenol hydrochloride	69097-521	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in ISOPROTERENOL?

# Of NDCs	Excipient
1	CITRIC ACID ACETATE
1	EDETATE DISODIUM
1	HYDROCHLORIC ACID

Isoproterenol Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Isoproterenol hydrochloride is an established, low-molecular-weight catecholamine supplied primarily as a sterile injectable. The commercial opportunity is not a new-molecule patent play. It is a formulation, packaging, supply-chain, and hospital-use opportunity focused on oxidation control, dosing convenience, preservative-free presentation, and reliable availability.

The strongest product concepts are:

1. A ready-to-use, single-dose, preservative-free syringe.
2. A stabilized multidose or single-dose vial with validated light and oxygen protection.
3. A premixed infusion presentation that reduces bedside dilution errors.
4. A low-extractables, low-adsorption package for emergency and electrophysiology use.
5. A differentiated product supported by stability data, device usability, and hospital procurement value rather than exclusivity claims.

Isoproterenol has limited conventional patent protection because its active ingredient and principal injectable uses are old. Commercial defensibility must come from formulation performance, container-closure design, manufacturing reliability, regulatory execution, and institutional contracts.

What is the current formulation profile of isoproterenol injection?

Isoproterenol hydrochloride is a water-soluble sympathomimetic agent administered parenterally. U.S. labeling identifies injectable presentations such as 0.2 mg/mL strength, with the active ingredient dissolved in water for injection and excipients used to control tonicity and pH.[1]

Attribute	Formulation implication
Active ingredient	Isoproterenol hydrochloride
Dosage form	Sterile aqueous injection
Typical strength	0.2 mg/mL in marketed U.S. presentations
Primary administration	Intravenous infusion or injection, depending on clinical use
Chemical class	Catecholamine sympathomimetic
Main degradation concern	Oxidative degradation and color change
Main packaging concern	Light exposure, oxygen ingress, adsorption, and extractables
Typical hospital setting	Critical care, emergency medicine, cardiology, electrophysiology
Primary commercial need	Ready availability and reduced preparation complexity

Catecholamine products require careful control of oxygen exposure, trace metals, light, pH, and container-closure performance. Formulation development should treat discoloration as an early indicator of chemical instability, but appearance alone is not a sufficient stability specification. Assay, related substances, particulate matter, sterility, endotoxins, pH, and container-closure integrity require direct testing.

Which excipients are most suitable for isoproterenol injection?

The preferred starting platform is a simple aqueous, isotonic, buffered formulation with a conservative excipient burden. The formulation should avoid unnecessary preservatives and should be compatible with the intended container and administration route.

Buffer systems

Citrate-based buffering is a rational platform for an isoproterenol injection because marketed products use citrate-related pH control in at least some presentations.[1] A citrate system can provide:

• pH control during sterilization and storage;
• compatibility with an aqueous injectable;
• a familiar excipient profile for FDA review;
• low formulation complexity.

Phosphate buffers may be technically feasible but require more extensive compatibility and precipitation testing. The final buffer should be selected through a pH-rate study rather than by assuming that the most acidic formulation is optimal. Excessively low pH can create tolerability and compatibility concerns, while higher pH can accelerate catechol oxidation.

Tonicity agents

Sodium chloride is the most straightforward tonicity agent for an injectable product. The target should be justified against the final concentration, infusion dilution practices, and route of administration. A formulation that is isotonic or near-isotonic can simplify clinical handling, but excessive sodium content may matter for patients receiving multiple critical-care infusions.

Alternative tonicity agents, including dextrose or mannitol, would create additional compatibility and stability questions. They may be useful in a specialized premix but offer limited strategic value in a conventional vial or syringe unless the product is designed for a specific infusion protocol.

Antioxidants and chelating agents

Sodium metabisulfite and related sulfiting agents can reduce oxidative degradation in some catecholamine formulations. Their use creates a tradeoff:

• improved chemical stability may be achieved;
• sulfite sensitivity and labeling obligations are introduced;
• compatibility with institutional preferences may decline;
• the formulation becomes less attractive for patients or protocols that avoid sulfites.

Disodium edetate or another suitable chelating agent may reduce trace-metal-catalyzed oxidation. Its concentration must be minimized and justified through a metal-challenge study. Chelators can affect container systems, analytical methods, and compatibility with other infusion components.

A high-value development program should compare at least four arms:

Development arm	Antioxidant	Chelator	Commercial rationale
A	None	None	Simplest label and lowest excipient burden
B	Sulfite	None	Potentially stronger oxidation control
C	None	EDTA-type chelator	Sulfite-free stability strategy
D	Sulfite	EDTA-type chelator	Maximum stabilization, highest regulatory and labeling burden

The decision should be based on impurity growth, color, oxygen sensitivity, sterilization impact, and long-term stability. The most defensible formulation is not necessarily the one with the longest accelerated stability result. A sulfite-free product with adequate shelf life may have greater hospital acceptance and a simpler risk profile.

Preservatives

A preservative-free, single-dose presentation is commercially preferable for emergency and cardiac use. Benzyl alcohol, phenol, and related preservatives can create population-specific concerns and may complicate neonatal, pediatric, or high-acuity use. A multidose presentation would require a specific contamination-control strategy and a clear clinical rationale.

What formulation patents protect isoproterenol injection?

No current core active-ingredient patent is expected to block development of a standard isoproterenol hydrochloride injection. The molecule, basic injectable use, and conventional excipients are old technologies. The relevant intellectual-property risks are more likely to involve:

• a specific stabilized composition;
• a premixed infusion concentration;
• a syringe or cartridge configuration;
• a low-oxygen or light-protective container system;
• a manufacturing process;
• a device or administration system;
• a branded product’s trade dress or proprietary presentation.

IP category	Likely risk level	Strategic assessment
Isoproterenol molecule	Low	Long-established active ingredient
Conventional aqueous injection	Low	Common formulation technology
Citrate and sodium chloride system	Low	Generic excipient platform
Sulfite or chelator stabilization	Low to moderate	Potentially claimable only with narrow, differentiated performance
Ready-to-use syringe	Moderate	Device, packaging, and presentation claims may apply
Premixed infusion bag	Moderate	Composition and use claims require clearance
Low-oxygen packaging	Moderate	May involve proprietary container or manufacturing methods
Method of use	Low for established indications	Older clinical uses are generally weak exclusivity assets
Manufacturing process	Product-specific	Clearance depends on process claims and jurisdiction

A new applicant should conduct a freedom-to-operate search covering U.S. patents, PCT filings, European national rights, Japan, China, and major Latin American markets. The search should include the terms isoproterenol, isoprenaline, catecholamine injection, oxygen-stabilized injection, ready-to-use syringe, and emergency cardiac infusion.

When does isoproterenol lose exclusivity?

Isoproterenol has already lost basic small-molecule exclusivity in the United States. The commercial market is therefore governed by generic competition, product availability, manufacturing capacity, and regulatory status rather than by a pending compound-patent expiration date.

Exclusivity component	Current commercial relevance
New chemical entity exclusivity	Expired
Core compound patent	Expected to be expired
Conventional injectable composition patent	Unlikely to create a durable barrier
Method-of-use exclusivity	Limited for established uses
Orphan-drug exclusivity	Not the principal market structure
Biosimilar exclusivity	Not applicable
FDA 180-day generic exclusivity	Possible only if tied to a qualifying ANDA Paragraph IV event
Formulation or device exclusivity	Possible for a newly approved differentiated product

A differentiated product could obtain limited regulatory exclusivity only if it qualifies under a specific FDA pathway, such as a new drug application with a qualifying innovation. A conventional ANDA generally does not create broad market exclusivity unless the applicant is a first filer with a qualifying Paragraph IV certification.

What is the Orange Book status of isoproterenol?

The Orange Book remains the central source for identifying listed U.S. drug products, therapeutic equivalents, patent information, and exclusivity data.[2] Isoproterenol injection should be assessed by:

1. identifying all active reference-listed drugs;
2. reviewing therapeutic-equivalence codes;
3. checking listed patents and exclusivity entries;
4. confirming whether the relevant product is discontinued, active, or reference-listed;
5. reviewing FDA’s Approved Drug Product List and supplemental updates.

For an isoproterenol injection developer, the principal Orange Book risk is unlikely to be a blocking patent on the active ingredient. The important issue is whether the proposed strength, dosage form, route, and labeling can support an ANDA against a current reference product. A formulation that differs materially in excipient composition may require comparative studies or a different regulatory strategy if the difference affects safety, effectiveness, or labeling.

What Paragraph IV challenges could affect isoproterenol?

Paragraph IV litigation is likely to have limited strategic value for a conventional isoproterenol injectable because the underlying technology is mature and patent density is low. A Paragraph IV challenge could still arise if a listed patent covers:

• a specific stabilizer combination;
• a particular concentration;
• a ready-to-use device;
• an extended shelf-life claim;
• a formulation with a defined impurity profile.

The applicant would need to evaluate patent listing accuracy, claim scope, expiration, enforceability, and whether the proposed product infringes. A Paragraph IV filing can produce 30-month litigation-related delays under the Hatch-Waxman framework if the statutory conditions are met.[3]

For a new product, a 505(b)(2) pathway may be more suitable when the formulation, container, or clinical presentation differs from the reference product in a way that is not readily addressed through ANDA sameness requirements. A 505(b)(2) strategy would not automatically create strong exclusivity, but it could support a differentiated label and product profile.

What excipient strategy creates the strongest commercial product?

The strongest base-case formulation is a preservative-free aqueous injection using:

• isoproterenol hydrochloride;
• water for injection;
• sodium chloride or another validated tonicity agent;
• a citrate-based buffer;
• optional low-level chelation if stability data support it;
• oxygen- and light-controlled packaging.

The highest-priority development studies are:

Study	Business purpose
pH-rate profile	Defines the stability and tolerability window
Oxygen challenge	Quantifies headspace and oxygen sensitivity
Trace-metal challenge	Tests the value of a chelator
Light-exposure study	Supports packaging and label storage conditions
Sterilization comparison	Compares terminal sterilization with aseptic processing
Container compatibility	Measures adsorption, leachables, and extractables
Dilution compatibility	Supports emergency and infusion use
In-use stability	Defines post-opening and post-dilution handling
Freeze-thaw study	Supports distribution resilience
Particulate and subvisible-particle study	Reduces injectable quality risk

Container selection may be more commercially important than a small change in excipient composition. Candidate systems include Type I glass ampules, glass vials, polymer vials, prefilled glass syringes, and cyclic olefin polymer systems. The preferred container should be selected using a combined assessment of oxygen transmission, light protection, breakage risk, syringe functionality, siliconization, tungsten residues, extractables, and automated compounding compatibility.

What ready-to-use products could compete with standard isoproterenol vials?

Prefilled syringe

A prefilled syringe is the clearest premium opportunity. It can reduce bedside preparation, lower dilution errors, and improve response time in emergency and electrophysiology settings. The product would need validated syringe stability, plunger compatibility, dose accuracy, needle or luer configuration, and appropriate labeling for direct administration or dilution.

The main risk is cost. A syringe may command a premium only where labor savings, medication safety, or emergency readiness are measurable.

Premixed infusion bag

A small-volume premixed bag could target intensive-care and cardiac units. The value proposition is standardized concentration and reduced pharmacy compounding. The formulation must address bag adsorption, oxygen ingress, overwrap requirements, terminal sterilization, and compatibility with common infusion sets.

Single-dose vial

A single-dose vial is the lowest-risk commercial extension. It can improve supply reliability while preserving familiar hospital workflows. Its differentiation would depend on shelf life, package size, fill volume, presentation, and availability rather than formulation novelty.

Ampule replacement

A break-resistant vial or polymer container could replace glass ampules in institutions concerned with sharps injury, glass particles, or preparation time. The product must prove equivalent chemical stability and particulate performance.

How does isoproterenol compare with competing catecholamine products?

Isoproterenol competes indirectly with other agents used for bradycardia, chronotropic support, or hemodynamic management. The relevant competitors include epinephrine, dopamine, dobutamine, and atropine, although their clinical roles are not interchangeable.

Product	Primary commercial differentiation	Excipient opportunity
Isoproterenol	Chronotropic and beta-adrenergic use	Ready-to-use cardiac emergency presentation
Epinephrine	Broad emergency use	Autoinjectors, syringes, premixes
Dopamine	Vasopressor and inotropic use	Premixed bags and infusion standardization
Dobutamine	Inotropic support	Premixed infusion systems
Atropine	Bradycardia treatment	Prefilled emergency formats

Isoproterenol’s opportunity is narrower than epinephrine’s but can be attractive because specialized cardiac users may value predictable access and a standardized presentation. The product should be marketed around clinical workflow, not broad therapeutic substitution.

Which companies are challenging the isoproterenol market?

The competitive field consists primarily of generic injectable manufacturers, hospital suppliers, contract manufacturers, and specialty pharmaceutical companies. Competition can arise through:

• ANDA-approved injectable products;
• authorized generic or legacy branded products;
• hospital contracts;
• shortage-driven sourcing;
• private-label manufacturing;
• pharmacy-compounded alternatives;
• ready-to-use emergency products.

The most important competitive variables are FDA-approved supply, manufacturing reliability, shortage history, lead time, minimum order quantity, vial or syringe format, and wholesaler access. Biosimilar competition is irrelevant because isoproterenol is a synthetic small molecule, not a biologic.

What manufacturing and IP barriers affect commercial entry?

Manufacturing is the main practical barrier. Isoproterenol development requires control of:

• raw-material oxidation;
• solution color;
• oxygen exposure during compounding;
• pH drift;
• sterile filtration or terminal sterilization;
• container-closure integrity;
• visible and subvisible particles;
• endotoxins;
• extractables and leachables;
• cold-chain or controlled-room-temperature distribution, depending on validated stability.

A manufacturer with an established sterile-injectable facility has a material advantage over a sponsor that must build capability from scratch. Contract manufacturing can accelerate entry, but capacity reservations, technology transfer, aseptic-process validation, and inspection readiness can determine launch timing.

What is the generic launch risk for an improved isoproterenol product?

Generic launch risk is moderate for a standard vial and higher for a differentiated syringe or premix. The core active ingredient is mature, but injectable products have greater operational risk than oral generics.

Launch scenario	Regulatory risk	Commercial upside
Standard single-dose vial	Low to moderate	Moderate
Preservative-free vial with longer shelf life	Moderate	Moderate to high
Prefilled syringe	Moderate to high	High
Premixed infusion bag	High	High in institutional channels
Novel excipient stabilization	Moderate	Depends on measurable shelf-life gain
Polymer container	Moderate	Potential workflow and safety advantage

A successful launch should secure dual-source raw materials, validate a backup fill-finish site, and establish a shortage-response plan. Hospitals may change suppliers quickly when a critical injectable becomes unavailable, but they also require reliable quality, standardized packaging, and consistent delivery.

What are the licensing and partnership opportunities?

Licensing is more likely to involve manufacturing, packaging, or distribution than a proprietary active-ingredient patent. Attractive partnership structures include:

• licensing a prefilled-syringe platform;
• co-development with a sterile-injectable manufacturer;
• hospital-system supply agreements;
• private-label distribution through a generic specialist;
• regional rights for ready-to-use products;
• contract packaging for ampule-to-vial conversion;
• acquisition of an established ANDA or approved product.

A formulation patent can improve bargaining position only if it covers a measurable product advantage and survives validity and infringement review. A stronger commercial package combines regulatory approval, validated shelf life, supply capacity, and institutional adoption data.

Key Takeaways

• Isoproterenol is a mature small-molecule injectable with little expected core patent protection.
• Oxidative degradation, light exposure, oxygen ingress, and container compatibility are the central formulation issues.
• A citrate-buffered, isotonic, preservative-free aqueous formulation is the strongest baseline platform.
• Sulfites may improve stability but create labeling and market-acceptance tradeoffs.
• A chelator may support a sulfite-free strategy if trace-metal studies show a meaningful benefit.
• The best commercial opportunities are prefilled syringes, premixed infusion products, and reliable single-dose vials.
• Orange Book and Paragraph IV risks are likely to be limited unless a new product claims a specific formulation, device, or presentation.
• Manufacturing reliability and hospital workflow value are more important than traditional compound-patent exclusivity.
• Biosimilar competition does not apply.
• Licensing value is concentrated in sterile manufacturing, ready-to-use packaging, distribution, and institutional supply contracts.

FAQs

Is isoproterenol injection sensitive to light?

Yes. Light exposure should be evaluated as part of forced-degradation and long-term stability programs. Light-protective packaging, controlled storage, and an appropriate label may be required.

Can sodium metabisulfite be used in isoproterenol injection?

It can be evaluated as an antioxidant, but its use introduces sulfite-related labeling and tolerability considerations. The benefit should be demonstrated against a sulfite-free formulation.

Is a prefilled isoproterenol syringe eligible for an ANDA?

Potentially, if it meets the applicable sameness and pharmaceutical-equivalence requirements. A material difference in device, formulation, concentration, or administration method may require a 505(b)(2) strategy.

Does isoproterenol have biosimilar risk?

No. Isoproterenol is a synthetic small molecule. Competitive entry occurs through generic, branded-generic, or differentiated injectable pathways.

What is the most defensible isoproterenol product strategy?

A preservative-free, ready-to-use syringe or standardized single-dose vial with validated oxidation control, light protection, long shelf life, and dependable hospital distribution offers the strongest balance of regulatory feasibility and commercial differentiation.

References

1. DailyMed. (n.d.). Isoproterenol hydrochloride injection, USP prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations, 37th edition.
4. U.S. Food and Drug Administration. (2020). Inactive ingredient database.
5. U.S. Food and Drug Administration. (1997). 21 CFR Part 314: Applications for FDA approval to market a new drug.
6. U.S. Food and Drug Administration. (2003). Guidance for industry: ANDAs for certain highly purified synthetic drug substances.
7. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.
8. International Council for Harmonisation. (2023). Q3D(R2): Guideline for elemental impurities.
9. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.